Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Walter Pugh

Internal Medicine Greenville, SC Medical Doctor

NPI 1770632762 CMS profile 352479

2 Innovation Dr Ste 300, Greenville, SC 29607

Open in the dashboard

General payments

$10,181

606 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Walter Pugh of Greenville, SC is reported in the CMS Open Payments database as having received $10,181 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,254 64
2022 General $2,102 125
2021 General $2,475 153
2020 General $1,916 126
2019 General $2,434 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walter Pugh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Walter Pugh were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Walter Pugh Internal Medicine median Middle half National median
2019 $2,434 $159 $48–$570 $163
2020 $1,916 $119 $33–$402 $114
2021 $2,475 $135 $37–$521 $132
2022 $2,102 $141 $42–$496 $149
2023 $1,254 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $1,296 90 payments
  2. AbbVie, Inc. $870 59 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $702 36 payments
  4. AstraZeneca Pharmaceuticals LP $684 42 payments
  5. Amgen Inc. $622 27 payments
  6. Amarin Pharma Inc. $597 28 payments
  7. Dexcom, Inc. $544 18 payments
  8. Janssen Pharmaceuticals, Inc $539 33 payments
  9. Lilly USA, LLC $446 30 payments
  10. Pfizer Inc. $428 34 payments
  11. Other $3,451 209 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $10,181 606 payments
Products named General payments · program years 2019–2023
  1. Ozempic $1,012 65 payments
  2. RYBELSUS $881 57 payments
  3. JARDIANCE $702 36 payments
  4. FARXIGA $479 27 payments
  5. AIMOVIG $414 20 payments
  6. XARELTO $406 30 payments
  7. Dexcom G6 Transmitter $372 14 payments
  8. Vascepa $363 21 payments
  9. XIFAXAN $330 21 payments
  10. UBRELVY $325 17 payments
  11. Other $8,067 516 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,510

Median for Internal Medicine: 777

Drug cost

$155,948

Median for Internal Medicine: $73,373

Branded share of claims

15.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 32 $41,589
Ozempic Semaglutide Brand 30 $29,843
Farxiga Dapagliflozin Propanediol Brand 12 $20,577
Xarelto Rivaroxaban Brand 15 $18,503
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $8,264
Myrbetriq Mirabegron Brand 12 $7,434
Synthroid Levothyroxine Sodium Brand 22 $1,899
Atorvastatin Calcium Generic 188 $1,636
Levothyroxine Sodium Generic 127 $1,598
Rosuvastatin Calcium Generic 110 $1,493

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record